Biogen Stock Sinks on Lackluster Alzheimer's News

Dow Jones07-14

Biogen stock was down more than 7% Tuesday morning--on pace for its largest drop since 2020--after the company's tau-targeting drug failed to perform any better than the Alzheimer's drugs already on the market. On a standard dementia scale, patients taking Biogen's experimental drug diranersen saw a 26% slowing in the rate of cognitive decline, roughly in line with the company's drug Leqembi.

Diranersen, which failed to meet its primary goal in a clinical trial in May, did succeed in cutting a protein called tau in patients' spinal fluid by as much as 65%, according to data presented Tuesday at the Alzheimer's Association International Conference. The company says it plans to move the drug into late-stage testing.

--Tau is the target of a growing wave of Alzheimer's research, as drugmakers look for more potent ways to slow the disease after the first few approved drugs showed just modest benefit.

--Tuesday's drop comes a day after Biogen shares jumped 5% Monday, after the Food and Drug Administration approved an at-home, self-administered starter dose of Leqembi. Previously, that initial treatment was only available through infusions given at a clinic.

Write to Xavier Martinez at xavier.martinez@wsj.com

(END) Dow Jones Newswires

July 14, 2026 11:56 ET (15:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651107045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 23:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651107045","market":"nz","top_or_hot":-1,"title":"Biogen Stock Sinks on Lackluster Alzheimer's News","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Biogen stock was down more than 7% Tuesday morning--on pace for its largest drop since 2020--after the company's tau-targeting drug failed to perform any better than the Alzheimer's drugs already on the market. On a standard dementia scale, patients taking Biogen's experimental drug diranersen saw a 26% slowing in the rate of cognitive decline, roughly in line with the company's drug Leqembi. \n</p>\n<p>\n  Diranersen, which failed to meet its primary goal in a clinical trial in May, did succeed in cutting a protein called tau in patients' spinal fluid by as much as 65%, according to data presented Tuesday at the Alzheimer's Association International Conference. The company says it plans to move the drug into late-stage testing. \n</p>\n<p>\n  --Tau is the target of a growing wave of Alzheimer's research, as drugmakers look for more potent ways to slow the disease after the first few approved drugs showed just modest benefit. \n</p>\n<p>\n  --Tuesday's drop comes a day after Biogen shares jumped 5% Monday, after the Food and Drug Administration approved an at-home, self-administered starter dose of Leqembi. Previously, that initial treatment was only available through infusions given at a clinic. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Xavier Martinez at xavier.martinez@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 11:56 ET (15:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Stock Sinks on Lackluster Alzheimer's News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Stock Sinks on Lackluster Alzheimer's News\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-14 23:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Biogen stock was down more than 7% Tuesday morning--on pace for its largest drop since 2020--after the company's tau-targeting drug failed to perform any better than the Alzheimer's drugs already on the market. On a standard dementia scale, patients taking Biogen's experimental drug diranersen saw a 26% slowing in the rate of cognitive decline, roughly in line with the company's drug Leqembi. \n</p>\n<p>\n  Diranersen, which failed to meet its primary goal in a clinical trial in May, did succeed in cutting a protein called tau in patients' spinal fluid by as much as 65%, according to data presented Tuesday at the Alzheimer's Association International Conference. The company says it plans to move the drug into late-stage testing. \n</p>\n<p>\n  --Tau is the target of a growing wave of Alzheimer's research, as drugmakers look for more potent ways to slow the disease after the first few approved drugs showed just modest benefit. \n</p>\n<p>\n  --Tuesday's drop comes a day after Biogen shares jumped 5% Monday, after the Food and Drug Administration approved an at-home, self-administered starter dose of Leqembi. Previously, that initial treatment was only available through infusions given at a clinic. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Xavier Martinez at xavier.martinez@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 11:56 ET (15:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651107045","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651107045","pubTimestamp":1784044560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Biogen stock was down more than 7% Tuesday morning--on pace for its largest drop since 2020--after the company's tau-targeting drug failed to perform any better than the Alzheimer's drugs already on t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司","BMED":"iShares Health Innovation Active ETF","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4533":"AQR资本管理(全球第二大对冲基金)","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF"},"translate_title":"由于阿尔茨海默氏症消息黯淡，百健股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMED":0.6,"BIIB":1.5,"PBE":0.6},"content_text":"Biogen stock was down more than 7% Tuesday morning--on pace for its largest drop since 2020--after the company's tau-targeting drug failed to perform any better than the Alzheimer's drugs already on the market. On a standard dementia scale, patients taking Biogen's experimental drug diranersen saw a 26% slowing in the rate of cognitive decline, roughly in line with the company's drug Leqembi. \n\n\n  Diranersen, which failed to meet its primary goal in a clinical trial in May, did succeed in cutting a protein called tau in patients' spinal fluid by as much as 65%, according to data presented Tuesday at the Alzheimer's Association International Conference. The company says it plans to move the drug into late-stage testing. \n\n\n  --Tau is the target of a growing wave of Alzheimer's research, as drugmakers look for more potent ways to slow the disease after the first few approved drugs showed just modest benefit. \n\n\n  --Tuesday's drop comes a day after Biogen shares jumped 5% Monday, after the Food and Drug Administration approved an at-home, self-administered starter dose of Leqembi. Previously, that initial treatment was only available through infusions given at a clinic. \n\n\n \n\n\n  Write to Xavier Martinez at xavier.martinez@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 14, 2026 11:56 ET (15:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651107045","isCrawlerRequest":true}